Senior Director, Business Development at evitria
Mail: rp@evitria.com
Starting at evitria in 2020 as Director of Client Relations, Richard Park has been Senior Director, Business Development at Evitria since 2024. This makes him the interface between clients and the company, specialized in providing service solutions for expression and purification in the antibody production.
Richard Park graduated from Brown University with Bachelor’s degrees in French studies and biomedical engineering, the latter of which he concluded with a thesis on the “Dilutive effects of protein-SDS complexes in microfluidic gel electrophoresis”. Consequently, he has gained broad experience in the biotechnology industry as well as being concerned with civil rights and social actions.
LinkedIn profile: Richard Park
Articles
There can be several reasons to outsource the production of antibodies to specialized CROs and CDMOs. This article illustrates what should be considered when choosing a partner in antibody production.
The term “in vivo antibodies” is somewhat ambiguous, as it can describe both antibodies that are produced in vivo and those that are designed for in vivo applications. Both aspects will be discussed in this article.
Antibody production is performed in a set of distinctive steps, requiring expert knowledge and devices. In this article, we will take a look at these individual steps and highlight some challenges and considerations.